Terms: = Breast cancer AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Prognosis
46 results:
1. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
[TBL] [Abstract] [Full Text] [Related]
2. Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic breast cancer: Analysis of ECOG-ACRIN E2112.
Ballinger TJ; Marques HS; Xue G; Hoffman R; Gatsonis C; Zhao F; Miller KD; Sparano J; Connolly RM
J Natl Compr Canc Netw; 2023 Sep; 21(9):915-923.e1. PubMed ID: 37673107
[TBL] [Abstract] [Full Text] [Related]
3. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal cancer and Invasive breast cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract] [Full Text] [Related]
4. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
[TBL] [Abstract] [Full Text] [Related]
5. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early breast cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of machine learning algorithms for the prognosis of breast cancer from the Surveillance, Epidemiology, and End Results database.
Wu R; Luo J; Wan H; Zhang H; Yuan Y; Hu H; Feng J; Wen J; Wang Y; Li J; Liang Q; Gan F; Zhang G
PLoS One; 2023; 18(1):e0280340. PubMed ID: 36701415
[TBL] [Abstract] [Full Text] [Related]
7. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V; Schmidt CE; Lennartz M; Höflmayer D; Hube-Magg C; Weidemann S; Fraune C; Büscheck F; Möller K; Bernreuther C; Simon R; Clauditz TS; Blessin NC; Bady E; Sauter G; Uhlig R; Steurer S; Minner S; Burandt E; Dum D; Marx AH; Krech T; Lebok P; Hinsch A; Jacobsen F
Pathobiology; 2023; 90(4):219-232. PubMed ID: 36649695
[TBL] [Abstract] [Full Text] [Related]
8. Exploration of the immune microenvironment of breast cancer in large population cohorts.
Deng Y; Wang J; Hu Z; Cai Y; Xu Y; Xu K
Front Endocrinol (Lausanne); 2022; 13():955630. PubMed ID: 36046784
[TBL] [Abstract] [Full Text] [Related]
9. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
Gampenrieder SP; Rinnerthaler G; Tinchon C; Petzer A; Balic M; Heibl S; Schmitt C; Zabernigg AF; Egle D; Sandholzer M; Singer CF; Roitner F; Hager C; Andel J; Hubalek M; Knauer M; Greil R
Breast Cancer Res; 2021 Dec; 23(1):112. PubMed ID: 34906198
[TBL] [Abstract] [Full Text] [Related]
10. DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples.
Jansen K; Farahi N; Büscheck F; Lennartz M; Luebke AM; Burandt E; Menz A; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Lebok P; Sauter G; Simon R; Uhlig R; Wilczak W; Jacobsen F; Minner S; Krech R; Clauditz T; Bernreuther C; Dum D; Krech T; Marx A; Steurer S
Pathol Res Pract; 2021 Dec; 228():153663. PubMed ID: 34717148
[TBL] [Abstract] [Full Text] [Related]
11. Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
Sajjadi E; Venetis K; Piciotti R; Gambini D; Blundo C; Runza L; Ferrero S; Guerini-Rocco E; Fusco N
BMC Cancer; 2021 Oct; 21(1):1152. PubMed ID: 34706703
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.
Mutai R; Barkan T; Moore A; Sarfaty M; Shochat T; Yerushalmi R; Stemmer SM; Goldvaser H
Breast; 2021 Dec; 60():62-69. PubMed ID: 34481367
[TBL] [Abstract] [Full Text] [Related]
13. Application of deep learning in the detection of breast lesions with four different breast densities.
Li H; Ye J; Liu H; Wang Y; Shi B; Chen J; Kong A; Xu Q; Cai J
Cancer Med; 2021 Jul; 10(14):4994-5000. PubMed ID: 34132495
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors.
Menz A; Weitbrecht T; Gorbokon N; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Bernreuther C; Lebok P; Clauditz T; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Burandt E; Krech R; Dum D; Krech T; Marx A; Simon R
Mol Med; 2021 Feb; 27(1):16. PubMed ID: 33588765
[TBL] [Abstract] [Full Text] [Related]
15. Predicting the Incidence and prognosis of Bone Metastatic breast cancer: A SEER-Based Observational Study.
Shi D; Bai J; Chen Y; Wang X; Zhang Y; Liu H
Biomed Res Int; 2020; 2020():1068202. PubMed ID: 33294433
[TBL] [Abstract] [Full Text] [Related]
16. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer.
Skinner KE; Haiderali A; Huang M; Schwartzberg LS
Future Oncol; 2021 Mar; 17(8):931-941. PubMed ID: 33207944
[No Abstract] [Full Text] [Related]
17. Real-world assessment of the effect of impact of tumor size on pathological complete response rates in triple negative breast cancer after neoadjuvant chemotherapy.
de Paula BHR; Kumar S; Morosini FM; Calábria Cardoso DEM; de Sousa CAM; Crocamo S
Chin Clin Oncol; 2020 Dec; 9(6):78. PubMed ID: 33183012
[TBL] [Abstract] [Full Text] [Related]
18. Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Christgen M; Gluz O; Harbeck N; Kates RE; Raap M; Christgen H; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Krabisch P; Just M; Augustin D; Graeser M; Baehner F; Wuerstlein R; Nitz U; Kreipe H;
Cancer; 2020 Nov; 126(22):4847-4858. PubMed ID: 32780421
[TBL] [Abstract] [Full Text] [Related]
19. Anemia and perioperative mortality in non-cardiac surgery patients: a secondary analysis based on a single-center retrospective study.
Luo X; Li F; Hu H; Liu B; Zheng S; Yang L; Gao R; Li Y; Xi R; He J
BMC Anesthesiol; 2020 May; 20(1):112. PubMed ID: 32393181
[TBL] [Abstract] [Full Text] [Related]
20. Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors.
Jung AY; Behrens S; Schmidt M; Thoene K; Obi N; Hüsing A; Benner A; Steindorf K; Chang-Claude J
Breast Cancer Res; 2019 Nov; 21(1):117. PubMed ID: 31694687
[TBL] [Abstract] [Full Text] [Related]
[Next]
